Holen Sie sich die Stockscreener-App
74.09
1.04%
-0.78
Handel nachbörslich:
74.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$74.87
Offen:
$75.23
24-Stunden-Volumen:
1.42M
Relative Volume:
0.86
Marktkapitalisierung:
$36.11B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
37.52
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
-2.26%
1M Leistung:
-1.88%
6M Leistung:
+0.27%
1J Leistung:
-22.96%
1-Tages-Spanne:
$74.05
$75.42
1-Wochen-Bereich:
$72.42
$76.75
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
74.09 | 36.11B | 10.40B | 980.00M | 1.61B | 1.9749 |
ISRG
Intuitive Surgical Inc
|
457.78 | 162.13B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.31 | 42.47B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.75 | 37.84B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
205.02 | 29.87B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
US Startup PerZeption Inc. Announces Collaboration with Alcon Research - Yahoo Finance
Earnings Preview: Alcon to Report Financial Results Pre-market on May 06 - Moomoo
Alcon Announces Results of 2026 Annual General Meeting - BioSpace
Alcon shareholders approve CHF 0.28 dividend, add Scott Herren - Stock Titan
Alcon Inc. Elects R. Scott Herren as New Independent Member of the Board - marketscreener.com
How Alcon Inc. (ALC) Affects Rotational Strategy Timing - Stock Traders Daily
Is Alcon Inc (ALC) a Bargain After 3.4% Drop? GF Value Says Unde - GuruFocus
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
World Council of Optometry and Alcon Video Series Summarizes TFOS DEWS III - InvisionMag.com
Alcon Inc. stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
STAAR Surgical falls as proxy adviser recommends against revised Alcon deal (update) - MSN
STAAR Surgical stock jumps 10% after Alcon sweetens buyout offer — investor says deal is 'worth substantially more' - MSN
STAAR Surgical vote on Alcon may be delayed againReport - MSN
Alcon Inc. (ALC) Stock Analysis: 24.91% Potential Upside Makes This Healthcare Giant Worth Watching - DirectorsTalk Interviews
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update) - MSN
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
STAAR Surgical's largest holder to vote against Alcon bid - MSN
Alcon slips as Q4 financial results miss on both lines - MSN
Sight Sciences awarded $55.4 million in patent case against Alcon By Investing.com - Investing.com Canada
Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com
Alcon’s $186 Million South Fort Worth Bet Aims To Turbocharge Jobs - Hoodline
Alcon Inc stock (CH0432492467): Is vision care growth strong enough to unlock new upside? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock new upside? - AD HOC NEWS
Alcon inks incentives deal for $186 million Fort Worth expansion - The Business Journals
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100 - GuruFocus
Alcon Inc stock (CH0432492467): Why does its eye care dominance matter more for U.S. investors now? - AD HOC NEWS
RBC Bullish on Alcon's FY26 Growth Outlook; Outperform Maintained - marketscreener.com
RBC Capital Initiates Alcon(ALC.US) With Buy Rating, Announces Target Price $102.51 - Moomoo
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential - Yahoo Finance
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady growth? - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for sustained U.S. investor - AD HOC NEWS
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - The Manila Times
National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of Others - GlobeNewswire Inc.
On the Record: Alcon invests $60M in Cabell County facility - MSN
Alcon Inc. (ALC) Stock Analysis: A 16.43% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady investor gains? - AD HOC NEWS
Alcon Inc. stock (CH0432492467): Is vision care dominance strong enough to unlock steady growth for - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough to unlock steady upside? - AD HOC NEWS
Systane Augentropfen: Eye Relief Demand Surges Amid Screen Time Boom - AD HOC NEWS
Systane Augentropfen: Dry Eye Relief Gains Traction Amid Screen Time Surge - AD HOC NEWS
Alcon Inc stock (CH0432492467): Is its eye care dominance strong enough for steady U.S. investor ret - AD HOC NEWS
Alcon Inc stock (CH0432492467): Why Google Discover changes matter more now - AD HOC NEWS
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
4.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):